Enhertu plus Perjeta showed superior PFS compared to THP in HER2-positive advanced/metastatic breast cancer, irrespective of prior treatment, hormone receptor status, or PIK3CA mutations. Enhertu plus ...
HER2-positive breast cancer, once associated with poor outcomes, now sees improved prognosis due to targeted therapies like Herceptin. Combination therapies and neoadjuvant treatments have enhanced ...
In patients with metastatic breast cancer (BC), the prevalence of brain metastases increased with each treatment line, rising the most among patients with hormone receptor (HR)–negative, human ...
In patients with heart failure (HF) caused by Chagas disease, sacubitril/valsartan was superior to enalapril for the composite primary endpoint, predominantly driven by a significant reduction in ...